Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q2 2021 Results - Earnings Call Transcript
03:57am, Tuesday, 10'th Aug 2021
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q2 2021 Results - Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue Estimates
06:28pm, Monday, 09'th Aug 2021
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -60.00% and -72.43%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for th
Recap: Apellis Pharmaceuticals Q2 Earnings
05:27pm, Monday, 09'th Aug 2021
Shares of Apellis Pharmaceuticals (NASDAQ:APLS) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 73.25% year over year to ($2.72), wh
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 06'th Aug 2021
WALTHAM, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the compan
WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of it
WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has enter
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 07'th Jul 2021
WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the compan
Apellis (APLS) Up on Tie-up With Beam for Novel Therapies
10:32am, Friday, 02'nd Jul 2021
Apellis (APLS) signs a collaboration deal with Beam Therapeutics to develop new treatments for complement-driven diseases. Shares rise.
Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders
05:48am, Thursday, 01'st Jul 2021
Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven diseases. The partnership will leverag
Collaboration combines Apellis' expertise in complement, a complex biological system, with Beam's proprietary base editing platform
Apellis Pharmaceuticals Goes After Alexion Blood Disorder Drugs
05:54pm, Thursday, 10'th Jun 2021
Investors seem to think that a drug from fledgling biotech Apellis Pharmaceuticals ( APLS , Financial) can go head-to-head with established treatments backed by a competitor 10 times its size.
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
05:31pm, Tuesday, 01'st Jun 2021
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive outcomes.
Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study
11:17am, Wednesday, 26'th May 2021
Apellis' (APLS) recently approved drug, Empaveli, demonstrates superiority in hemoglobin stabilization and reduction in LDH level in treatment-naive PNH patients.
Apellis-Sobi Partnered Pegcetacoplan Shows Clinically Meaningful Improvements in Rare Blood Disorder Study
08:21am, Tuesday, 25'th May 2021
Apellis Pharmaceuticals Inc (NASDAQ: APLS) and Swedish Orphan Biovitrum AB (SOBI) have reported positive top-line results from the Phase 3 PRINCE study evaluating Empaveli (pegcetacoplan) in tr
Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
07:54am, Tuesday, 25'th May 2021
STOCKHOLM, May 25, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (GLOBE NEWSWIRE) today reported positive top-line results from the
